Novartis AG vs NEOS S&P 500 High Income ETF — how do they compare? Novartis AG trades at $152.38 (market cap $295.37B), while NEOS S&P 500 High Income ETF trades at $54.19. The key difference: Novartis AG pays a 3.07% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | SPYI | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $168.62 | $54.19 |
52-Week Low | $119.31 | $47.98 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →